The hepcidin-ferroportin axis modulates liver endothelial cell BMP expression to influence iron homeostasis in mice
- PMID: 39437541
- DOI: 10.1182/blood.2024024795
The hepcidin-ferroportin axis modulates liver endothelial cell BMP expression to influence iron homeostasis in mice
Abstract
The liver hormone hepcidin regulates systemic iron homeostasis to provide enough iron for vital processes while limiting toxicity. Hepcidin acts by degrading its receptor ferroportin (encoded by Slc40a1) to decrease iron export to plasma. Iron controls hepcidin production in part by inducing liver endothelial cells (LECs) to produce bone morphogenetic proteins (BMPs) that activate hepcidin transcription in hepatocytes. Here, we used in vitro and in vivo models to investigate whether ferroportin contributes to LEC intracellular iron content to modulate BMP expression and, thereby, hepcidin. Quantitative proteomics of LECs from mice fed different iron diets demonstrated an inverse relationship between dietary iron and endothelial ferroportin expression. Slc40a1 knockdown primary mouse LECs and endothelial Slc40a1 knockout mice exhibited increased LEC iron and BMP ligand expression. Endothelial Slc40a1 knockout mice also exhibited altered systemic iron homeostasis with decreased serum and total liver iron but preserved erythropoiesis. Although endothelial Slc40a1 knockout mice had similar hepcidin expression to control mice, hepcidin levels were inappropriately high relative to iron levels. Moreover, when iron levels were equalized with iron treatment, hepcidin levels were higher in endothelial Slc40a1 knockout mice than in controls. Finally, LEC ferroportin levels were inversely correlated with hepcidin levels in multiple mouse models, and treatment of hepcidin-deficient mice with mini-hepcidin decreased LEC ferroportin expression. Overall, these data show that LEC ferroportin modulates LEC iron and consequently BMP expression to influence hepcidin production. Furthermore, LEC ferroportin expression is regulated by hepcidin, demonstrating a bidirectional communication between LECs and hepatocytes to orchestrate systemic iron homeostasis.
© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Conflict-of-interest disclosure: J.L.B. has owned equity in FerruMax Pharmaceuticals, a company focused on targeting repulsive guidance molecule family proteins (including hemojuvelin) and bone morphogenetic protein/transforming growth factor β superfamily signaling as hepcidin-modulating agents for the treatment of anemia and other iron disorders. J.L.B.’s interests were reviewed and managed by Massachusetts General Hospital and Mass General Brigham, in accordance with their conflict-of-interest policies. J.D.M. holds patents for methods for modulating ferritinophagy; reports research support from Novartis and Casma Therapeutics; and has consulted for Third Rock Ventures and Skyhawk Therapeutics, all unrelated to the work. C.-Y.W. is currently employed at Keros Therapeutics (Lexington, MA). Y. Xue is currently employed at Moderna Therapeutics (Cambridge, MA). The remaining authors declare no competing financial interests.
Comment in
-
BMPs and iron: the ins and outs.Blood. 2025 Feb 6;145(6):557-558. doi: 10.1182/blood.2024027052. Blood. 2025. PMID: 39913338 No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases